The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

PHOENIX, AZ – December 11, 2025 – PRESSADVANTAGE – Phoenix NP announced a continued rise in patient satisfaction across Arizona, noting that positive feedback has increased as more women seek safe, ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight management has undergone a seismic shift. Zealthy is one of the fastest-growing telehealth weight-loss platforms in the ...

The athletic apparel company said Chief Executive Officer Calvin McDonald will step down in January and relinquish his board ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

The House has spent much of the last two months of this year trying to catch up on its work. It passed 22 bills in one recent ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

We never know what demons other people are fighting, even if we think we see their problems from the outside. Those who struggle with obesity often have trouble with their self-esteem, body image, ...

The pharmaceutical giant Eli Lilly has once again raised the bar in the highly competitive obesity treatment market. New clinical trial data for its experime ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...